EY-Parthenon advised Labomar in the acquisition of Pharmia

Labomar, a distinguished Contract Development and Manufacturing Organisation (CDMO) that specializes in the research, development and production of innovative and high-quality dietary supplements, pharmaceuticals, medical devices, foods for special medical purposes, and cosmetics, has acquired Pharmia, a leading contract manufacturer of food supplements and medical devices (CE-marked products) in Finland.

EY-Parthenon supported Labomar throughout the transaction process by delivering financial and tax due diligence, along with tax structuring support. This transaction highlights EY-Parthenon’s capability to effectively serve leading international private equity clients through a multidisciplinary and data-driven advisory approach, ensuring an efficient and purpose-driven process for cross-border transactions.

More information can be found on Labomar's website here.

Below you can find a selection of EY-Parthenon's recent deal alerts and you can also find a more extensive list on our Transactions and Corporate Finance by EY-Parthenon page.